Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians

2Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Age-related macular degeneration (AMD) is a multifactorial genetic disease, with at least 52 identifiable associated gene variants at 34 loci, including variants in complement factor H (CFH) and age-related maculopathy susceptibility 2/high-temperature requirement A serine peptidase-1 (ARMS2/HTRA1). Genetic factors account for up to 70% of disease variability. However, population-based genetic risk scores are generally more helpful for clinical trial design and stratification of risk groups than for individual patient counseling. There is some evidence of pharmacogenetic influences on various treatment modalities used in AMD patients, including Age-Related Eye Disease Study (AREDS) supplements, photodynamic therapy (PDT), and anti-vascular endothelial growth factor (anti-VEGF) agents. However, there is currently no convincing evidence that genetic information plays a role in routine clinical care.

Cite

CITATION STYLE

APA

Nguyen, J., Brantley, M. A., & Schwartz, S. G. (2024). Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. Frontiers in Bioscience - Scholar. IMR Press Limited. https://doi.org/10.31083/j.fbs1601003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free